Simultaneous determination of cefdinir and cefixime in human plasma by RP-HPLC/UV detection method: Method development, optimization, validation, and its application to a pharmacokinetic study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 24, 2011, Pages 2423-2429

  Khan, Abbas ^a   Iqbal, Zafar ^a   Khan, Muhammad Imran ^a   Javed, Khalid ^a   Khan, Abad ^a   Ahmad, Lateef ^a   Shah, Yasar ^a   Nasir, Fazli ^a  

^a UNIVERSITY OF PESHAWAR   (Pakistan)

Author keywords

Cefdinir; Cefixime; Optimization; Pharmacokinetic study; Reversed phase high performance liquid chromatography; Validation

Indexed keywords

CEFDINIR; CEFIXIME; PHARMACOKINETIC STUDY; REVERSED-PHASE HIGH PERFORMANCE LIQUID-CHROMATOGRAPHY; VALIDATION;

LIQUID CHROMATOGRAPHY; LIQUIDS; PHARMACOKINETICS; PLASMA (HUMAN); SAMPLING;

OPTIMIZATION;

ACETONITRILE; CEFDINIR; CEFIXIME; METHANOL; TRICHLOROACETIC ACID; TRIFLUOROACETIC ACID;

AQUEOUS SOLUTION; ARTICLE; BLOOD SAMPLING; CHEMICAL MODIFICATION; DEPROTEINATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG STABILITY; FLOW RATE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SAMPLING; SENSITIVITY ANALYSIS; SEPARATION TECHNIQUE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VACUUM EXTRACTION; VALIDATION STUDY;

CEFIXIME; CEPHALOSPORINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; HUMANS;

EID: 79961009867     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2011.06.040     Document Type: Article

References (22)

1. Sumirtapura Y.C., Pamudji J.S., Ingriyani I., Sulistiyo W., Suhalim H. Acta Pharm. Indones. 2004, 29:50.
2. Parfitt K. Martindale The Complete Drug Reference 1999, The Pharmaceutical Press, London.
3. Guay D.R.P. Clin. Ther. 2002, 24:473.
4. Perry C.M., Scott L.J. Drugs 2004, 64:1433.
5. Sader H.S., Jones R.N. Expert Rev. Anti-infect. Ther. 2007, 5:29.
6. Guay D.R.P. Pediat. Infect. Dis. J. 2000, 19:S141.
7. Guay D.R.P. Drugs 2003, 63:2169.
8. Adam D., Hostalek U., Tröster K. Infect 1995, 23:S83-S86.
9. McMillan A., Young H. Int. J. STD AIDS 2007, 18:253.
10. Chen Z., Zhang J., Yu J., Cao G., Wu X., Shi Y. J. Chromatogr. B 2006, 834:163.
11. Hishida A., Ohishi K., Nagashima S., Kanamaru M., Obara M., Kitada A. Antimicrob. Agents Chemother. 1998, 42:1718.
12. Hadad G.M., Emara S., Mahmoud W.M.M. Chromatographia 2009, 70:1593.
13. Liu G., Sha R., Gao S., Shen Y., Wang S. Acta Pharmaceut. Sin. 1993, 28:216.
14. Yan Z., Rong H.E.J., Dong W.E.N.A. Chin. J. Hosp. Pharm. 2003.
15. Arshad H.M., Gauhar S., Bano R., Muhammad I.N. Jordan J. Pharm. Sci. 2009, 2:53.
16. Meng F., Chen X., Zeng Y., Zhong D. J. Chromatogr. B 2005, 819:277.
17. Nemutlu E., Kir S., Katlan D., Beksa M.S. Talanta 2009, 80:117.
18. Matsumoto Y. Chemotherapy 2000, 44:6.
19. Mcateer J.A., Hiltke M.F., Silber B., Faulkner R. Clin. Chem. 1987, 33:1788.
20. Pehourcq F., Jarry C. J. Chromatogr. A 1998, 812:159.
21. Epshtein N. Pharm. Chem. J. 2004, 38:212.
22. Khan M.I., Khan A., Iqbal Z., Ahmad L., Shah Y. Chromatographia 2010, 71:577.